Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CinnaGen cetuximab versus Erbitux with FOLFIRI in RAS wild-type metastatic colorectal cancer
IRCT2017110821315N10Phase 3Completed
- Sponsor
- CinnaGen
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, double-blind trial of cetuximab in colorectal cancer (CRC) (2 arms), sponsored by CinnaGen. Primary endpoint: Progression-free survival. Started Nov 2017; status: completed.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on IRCT2017110821315N10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2017110821315N10.